Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota ...

Acquired hypothalamic obesity is typically precipitated by hypothalamic insult from tumors, treatment, trauma, stroke, or ...

In a conversation with Pharmaceutical Executive DeYoung explains that an end-to-end patient support model is designed to ...

FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur. The rare disease space has always been uniquely difficult for drug ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

Founder, Infinitus, notes the the emerging themes at Access USA 2026, including regulatory shifts, the collapse of the traditional hub model, and the proliferation of fragmented AI point solutions. In ...

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...

Launched in January, TrumpRx.gov is part of a series of most-favored-nation deals struck between the Trump administration and ...

War in the Middle East disrupts pharmaceutical supply chains in the Gulf region, forcing drugmakers to reroute shipments of ...

Matthew Turner, President of Patient Affordability, Paysign, touches on how evolving payer tactics appear to be pushing ...

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical ...